|
|
(32 intermediate revisions by 6 users not shown) |
Line 1: |
Line 1: |
| {{BNU-CHINA/partials/header}} | | {{BNU-CHINA/partials/header}} |
| {{BNU-CHINA/partials/nav | PROJECT=focus}} | | {{BNU-CHINA/partials/nav | PROJECT=focus}} |
| + | {{BNU-CHINA/article/theme | color=#003a6c}} |
| + | |
| <html> | | <html> |
| <div class="main-container"> | | <div class="main-container"> |
| <div class="container-fluid page-heading" style="background-image: url(https://static.igem.org/mediawiki/2016/f/f4/T--BNU-China--project.jpg);"> | | <div class="container-fluid page-heading" style="background-image: url(https://static.igem.org/mediawiki/2016/f/f4/T--BNU-China--project.jpg);"> |
− | <h3> BACKGROUND </h3> | + | <h3> Background </h3> |
| </div> | | </div> |
− | <div>
| + | |
− | <div class="container page-story"> | + | <div class="page-story"> |
| + | |
| <article id="project" class="col-lg-10 col-lg-offset-1 col-md-12 col-md-offset-0 col-sm-offset-0 col-sm-12"> | | <article id="project" class="col-lg-10 col-lg-offset-1 col-md-12 col-md-offset-0 col-sm-offset-0 col-sm-12"> |
| <header class="page-header"> | | <header class="page-header"> |
| <h1>Background</h1> | | <h1>Background</h1> |
− | <small id="secondary-page-header">This is our background</small>
| |
| </header> | | </header> |
| | | |
− | <h2>overview</h2> | + | <h2>Overview</h2> |
− | <p>Cancer is the second most common cause of death worldwide, causing 14 million new cases and over 8 million deaths per year<sup><a href="#ref-1">[1]</a></sup>.</p> | + | <p>Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body, and it is the second most common cause of death worldwide, leading to 14 million new cases and over 8 million deaths per year<sup><a href="https://2016.igem.org/Team:BNU-China/Project#ref-1">[1]</a></sup>. Besides, The financial costs of treating cancer were estimated at 1.16 trillion US dollars per year as of 2010. It has become one of the great challenges human is facing nowadays.</p> |
| <figure class="text-center"> | | <figure class="text-center"> |
| <img src="https://static.igem.org/mediawiki/2016/b/b2/T--BNU-China--cancer.jpg" width="65%"> | | <img src="https://static.igem.org/mediawiki/2016/b/b2/T--BNU-China--cancer.jpg" width="65%"> |
Line 22: |
Line 24: |
| </figcaption> | | </figcaption> |
| </figure> | | </figure> |
− | <p>Anti-microtubule agents are well known to effectively treat many common cancers, such as breast cancer、ovarian cancer. These plant-derived chemicals kills cancer cells by obstructing microtubule function and consequently blocking cell division. Microtubules are an important cellular structure composed of two proteins: α-tubulin and β-tubulin. They are hollow rod shaped structures that are required for cell division, among other cellular functions. <sub><a href="#ref-2">[2]</a></sub>Microtubules are dynamic structures, meaning that they are either in assembly or in disassembly. The anti-microtubule agents can destroy the dynamic balance of microtubule, hence terminating cell mitosis and inducing the tumor cell apoptosis.</p> | + | <p>In order to conquer this serious problem, many medical scientists are devoted to exploit medicines that can target cancer cells. In 1962, paclitaxel was discovered in the bark of the Pacific yew, <i>Taxus brevifolia</i>, giving the name “paclitaxel”. Shortly after its discovery, taxanes have demonstrated a unique ability to palliate the symptoms of many types of advanced cancers, including carcinoma of the ovary, lung, head, neck, bladder, and esophagus. Good efficacy and little side effect quickly made the taxane class a most common addition to the chemotherapy against cancer in the past several decades.</p> |
− | <p>Anti-microtubule agents can be divided into two types. The first type inhibit assembly, such as vinca alkaloids, colchicine, podophyllotoxin and etc. Another type of anti-microtubule agents, e.g. taxanes and epothilones, interfere in disassembly.</p>
| + | |
− | <p>Paclitaxel was discovered in 1962 in the bark of the Pacific yew, Taxus brevifolia, giving the name “paclitaxel”. Shortly after its discovery, taxanes have demonstrated a unique ability to palliate the symptoms of many types of advanced cancers, including carcinoma of the ovary, lung, head and neck, bladder, and esophagus. Good efficacy and little side effect quickly made the taxane class of anti-microtubule anticancer agents a most common addition to the chemotherapeutic armamentarium against cancer in the past several decades. </p>
| + | |
| <figure class="text-center"> | | <figure class="text-center"> |
| <img src="https://static.igem.org/mediawiki/2016/7/70/T--BNU-China--taxol2.jpg" width="65%" > | | <img src="https://static.igem.org/mediawiki/2016/7/70/T--BNU-China--taxol2.jpg" width="65%" > |
| <figcaption> | | <figcaption> |
− | Fig.2 Ball-and-stick model of the Taxol | + | Fig.2 Ball-and-stick model of the taxol |
| </figcaption> | | </figcaption> |
| </figure> | | </figure> |
− | <p>The great commercial success of Paclitaxel and other anti-microtubule medicines has inspired pharmaceutical companies to extract and test similar compounds, farmers to grow related plants and R&D investment from public and private sectors.So an effective tool is being needed urgently to bring more convenient.</p> | + | <p>The great commercial success of Paclitaxel and other anti-microtubule medicines has inspired pharmaceutical companies to extract and test similar compounds, farmers to grow related plants. So an effective method is being needed urgently to discover many other similar compounds. Moreover, testing the concentration of paclitaxel from fermentation broths or plants are in high demand.</p> |
− | <p>As to our project this year, we modified the homo sapiens α-tubulin, connected it with luciferase report gene’s N terminal or C terminal, and we putted the modified α-tubulin and β-tubulin into E-coli to express our fusion proteins. Then we will get a kit containing the tubulins and buffer which has an appropriate condition verified by experiments. We call the kit “taxolight”, and it can do these things:</p> | + | <p>How to test the taxol and screening other compounds?<br />We determine to use microtubule for assisting.</p> |
− | <h3>1. drug screen</h3> | + | <p>As we all know, the mechanism of taxol is to kill cancer cells by obstructing the function of microtubule and consequently blocking cell division. Microtubules are a kind of important cellular structure composed of two monomers: α-tubulin and β-tubulin. These hollow rod shaped proteins are required for many cellular activities including cell division and transportation.<sup><a href="https://2016.igem.org/Team:BNU-China/Project#ref-2">[2]</a></sup> A dynamic equivalence are found in microtubules, meaning that protein monomers are assembling and disassembling at every moment. The anti-microtubule agents can destroy the dynamic balance in microtubules, hence terminating cell mitosis and inducing the tumor cell apoptosis.</p> |
− | <p>Anti-cancer agents especially paclitaxel have showed their magnificent power in clinical application, but also are a little unsatisfactory. We still need to look for new drugs that more effective.</p> | + | <p>There are two types of anti-microtubule agents. One type inhibits assembly, such as vinca alkaloids, colchicine, podophyllotoxin and etc. The other type interferes disassembly, like taxanes and epothilones.</p> |
− | <p>The existing method to screen anti-microtubule agents needs purifying tubulins of mammalian brains. It relies on the features of tubulins that the solution turbid will increase when then polymerize in vitro under 37℃. So using this method, we can get a polymerization curve shaped sigmoid formed by the liquid OD value to the soaking time, correspondingly, we can also get a de-polymerization curve when putting the tubulins into ice. When adding different anti-microtubule agents, polymerization of "S" type curve or pour de-polymerization of "S" type curve has different effects, and we can determine the role of the drug according to the change of curve. The defects of this method are as follows:</p> | + | <p>As for the discovery of anti-cancer compounds, we narrow down our sight to the anti-microtubule agents which are of great significance in cancer treatments.</p> |
| + | <p>As for our project this year, we modified the homo sapiens α-tubulin, ligated it with N/C terminal of the luciferase report gene fragments. Based on the principles of synthetic biology, we aimed to express the fusion proteins with α-tubulin and signaling residues. Then we made a kit containing the fusion α-tubulins and non-fusion β-tubulins with buffer which has an appropriate condition verified by experiments. We call the kit “taxolight”, and through which we can achieve these things below:</p> |
| + | <h3>Screening with high feasibility</h3> |
| + | <p>Anti-cancer agents especially paclitaxel have showed their powerful ability in clinical application. However, we still need to look for new drugs that are more effective.</p> |
| + | <p>The existing screening method of anti-microtubule agents needs to purify tubulins coming from mammalian brains. It heavily relies on the turbidity of tubulin solutions when they aggregate or disaggregate under certain temperatures <i>in vitro</i>. Once using this method, we can get a “S”-type standard aggregation curve based on the liquid OD value and the incubation time. Similarly, we can also get a standard disaggregation curve. When added different anti-microtubule agents, the aggregation/disaggregation curve will change correspondingly. Thus we can determine the role of the drug according to the change of curve.</p> |
| + | <p>The defects of this method are shown below:</p> |
| <ol> | | <ol> |
− | <li>The operation of exacting and purifying tubulin from animal brain is very complicated, and fresh brain tissues are needed, so that the experiment must be done within an hour after killing the animal. At the same time, the price of reagents in this experiment is expensive. The experiment period is long which takes 3 days to purify the tubulins.</li> | + | <li>The operation of extracting and purifying tubulin from animal brain is very complicated, and the experiment must be done within an hour after killing the animal. At the same time, the price of reagents in this experiment is expensive. The experiment period is long which takes no less than 3 days.</li> |
− | <li>The wave length of measuring the OD is 350nm, which is between ultraviolet light and visible light. This leads to a huge deviation, so the instrument requirement is strict. And because the 350nm wave length lies in the UV light region, quartz containers are needed, which costs a lot.</li> | + | <li>The wave length of measuring OD is 350nm, which is between ultraviolet light and visible light and always leads to a huge deviation. Also, the requirement of the testing instruments is high, quartz containers are needed as well, which cost a lot.</li> |
| </ol> | | </ol> |
− | <p>Our project avoids these drawbacks, and provides a new idea on the drug screen of anti-microtubule agents: using our kit, add the two kinds of quantitative modified α-tubulins withβ-tubulins and buffer, and put the quantitative sample, and then measure its fluorescence intensity. Paclitaxel can be set as a standard, and we can compare the new medicine with paclitaxel by comparing the fluorescence intensity. In this way, the primary invitro screening of compounds that can influence microtubules can be carried out using our kit, to further research and development of new anti-microtubule agents.</p> | + | <p>Our project avoids these drawbacks, and provides a new insight for the anti-microtubule drug screening. What we need is just a fluorescence microscope by using our kit.</p> |
− | <h3>2. Detect the existence</h3> | + | <p>Take paclitaxel as a control, we could test the fluorescence intensity of new medicine compared with paclitaxel's. In this way, further research and development of new anti-microtubule agents can be carried out easily than before.</p> |
− | <p>HPLC/RP-HPLC is one of the most common method for detecting paclitaxel now. It relies on pumps to pass a pressurized liquid solvent containing the sample mixture through a column filled with a solid adsorbent material. Each component in the sample interacts slightly differently with the adsorbent material, causing different flow rates for the different components and leading to the separation of the components as they flow out the column.</p> | + | |
| + | <h3>Detection in high sensitivity</h3> |
| + | <p>HPLC/RP-HPLC is one of the most common method to detect paclitaxel now. It relies on pumps to pass the sample through a column filled with solid adsorbent materials. Each component in the sample interacts differently with the adsorbent material, causing different flow rates and leading to the separation of the components as they flow out of the column.</p> |
| <figure class="text-center"> | | <figure class="text-center"> |
| <img src="https://static.igem.org/mediawiki/2016/c/c1/T--BNU-China--HPLC.jpg" width="65%"> | | <img src="https://static.igem.org/mediawiki/2016/c/c1/T--BNU-China--HPLC.jpg" width="65%"> |
Line 49: |
Line 57: |
| </figcaption> | | </figcaption> |
| </figure> | | </figure> |
− | <p>The shortcoming is that the progress need a long time, which is very unfavorable to the studies in laboratory. For example, in a laboratory which producing paclitaxel from fungus, detecting the concentration of the product may delay experiment process if there were no paclitaxel at all. So we need to develop an effective method to rapidly detect whether taxanes exist or not before measuring concentration, which our kit can achieve in order to accelerate research progresses.</p> | + | <p>This is a time-consuming process which is very unfavorable to the studies in laboratory. For example, in a laboratory which producing paclitaxel from fungus, detecting the concentration of the product may delay experiment process if there were no paclitaxel at all. So we need to develop an effective method to rapidly detect whether taxanes exist or not before measuring concentration. Our kit can reach the goal in order to accelerate research progresses.</p> |
− | <h3>3. Detect the concentration </h3> | + | <h3>Concentration detection</h3> |
− | <p>On the basis of successfully achieving the former functions, we still want to improve our kit, so that it can be more powerful. Our plan is: we can establish an intensity – concentration database of a certain medicine (e.g. paclitaxel), then we can use our “taxolight” to determine the concentration of this certain medicine conveniently.</p> | + | <p>Apart from our former achievements, optimization is also needed. An intensity-concentration database of certain medicines (e.g. paclitaxel) is being planned, then we can use our “taxolight” to determine the concentration of this certain medicine conveniently.</p> |
− | <p>There is a limiting condition when using our kit to determine the concentration that it must be ensured that the sample solution doesn’t have other anti-microtubule agents. Nevertheless, it still has a high value in use. For example, famers who plant taxus can use our kit to detect the concentration of taxanes in there plants. Taxus need two years to harvest. And different species of yew has different paclitaxel content, some even don’t contain paclitaxel. Paclitaxel content is also closely related to the planting technique and the environment. This summer, we went to Yunnan, where is famous for abundant Taxus. And at there, we learned a terrible thing: In 2001, many farmland in Maguan county are planted with taxus , but due to the lack of planting techniques, most of the taxus can’t be used . That caused a series bad consequences. If our kit can be used by famers, they will be able to detect conveniently and notice it early, thus the tragedy will be effectively prevented.</p> | + | <p>There is a limited issue that the sample solution must be ensured not containing other anti-microtubule agents. Nevertheless, it is still useful. For example, farmers who plant taxus can apply our kit to detect the concentration of taxanes in there plants. Moreover, factory can use our kit to test the concentration of taxol in their fermentation broth. In conclusion, our product can be popularized in many agent-specific tests.</p> |
− | <p>As a huge breakthrough in cancer treatment, anti-microtubule drugs are of great significance. Our project helps shed light on the standard screening in drug developmental phase. Moreover, with our further optimization, we hope that we can achieve a more accurate level in the quantification of taxol or other anti-microtubule drugs compared to conventional testing methods.</p>
| + | |
| | | |
| <div class="reference"> | | <div class="reference"> |
| <ol> | | <ol> |
− | <li>World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 1.1. d5ISBN 9283204298.</li> | + | <li id="ref-1">World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 1.1. d5ISBN 9283204298.</li> |
− | <li>Rowinsky EK, Donehower RC (Oct 1991). "The clinical pharmacology and use of anti-microtubule agents in cancer chemotherapeutics". Pharmacology.& Therapeutics. 52 (1): 35–84. doi:10.1016/0163-7258(91)90086-2. PMID 1687171.</li> | + | |
| + | <li id="ref-2">Rowinsky EK, Donehower RC (Oct 1991). "The clinical pharmacology and use of anti-microtubule agents in cancer chemotherapeutics". Pharmacology.& Therapeutics. 52 (1): 35–84. doi:10.1016/0163-7258(91)90086-2. PMID 1687171.</li> |
| </ol> | | </ol> |
| </div> | | </div> |
Line 64: |
Line 73: |
| </article> | | </article> |
| | | |
| + | </div> |
| | | |
− |
| |
− | </div>
| |
| <div id="footer"> | | <div id="footer"> |
| <div id="footer-div"> | | <div id="footer-div"> |
Line 74: |
Line 82: |
| <li><a href="https://2016.igem.org/Team:BNU-China/Model">Model</a></li> | | <li><a href="https://2016.igem.org/Team:BNU-China/Model">Model</a></li> |
| <li><a href="https://2016.igem.org/Team:BNU-China/Achievements">Achievements</a></li> | | <li><a href="https://2016.igem.org/Team:BNU-China/Achievements">Achievements</a></li> |
− | <li><a href="https://2016.igem.org/Team:BNU-China/Safety">Practices</a></li> | + | <li><a href="https://2016.igem.org/Team:BNU-China/Integrated_Practices">Practices</a></li> |
− | <li><a href="https://2016.igem.org/Team:BNU-China/Team">Safety</a></li> | + | <li><a href="https://2016.igem.org/Team:BNU-China/Safety">Safety</a></li> |
| + | <li><a href="https://2016.igem.org/Team:BNU-China/Team">Team</a></li> |
| </ul> | | </ul> |
| <span>© 2016 BNU</span> | | <span>© 2016 BNU</span> |
− | </div>
| |
− | </div>
| |
| </div> | | </div> |
| </div> | | </div> |
| | | |
| </html> | | </html> |